Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Moroxydine is a synthetic antiviral drug belonging to the class of heterocyclic biguanidines. It was originally developed for the treatment and prevention of influenza but has demonstrated activity against a broad range of DNA and RNA viruses, including herpes simplex virus, varicella-zoster virus, and others[1][4][7]. Its mechanism of action is not fully elucidated but appears to involve inhibition of viral RNA synthesis by targeting viral RNA-dependent RNA polymerase, thereby reducing viral replication[6][8]. Additionally, it may interfere with the virus-host cell system during early stages of infection and cause formation of nonfunctional early proteins that decrease synthesis of viral DNA[7][8]. Moroxydine has been used in pharmaceutical formulations for respiratory infections and remains an experimental agent in clinical research.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on moroxydine.